Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.44 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.35 |
| ▸ | ALPL | P05186 | 4/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.31 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18189413 | 0.78 | GRIA1 (0.38) | GRIA1CACNG8PGK1SLC1A5ALPL | |
| SCHEMBL20118728 | 0.74 | GRIA1 (0.43) | GRIA1CACNG8 | |
| SCHEMBL2304247 | 0.73 | ALPL (0.40) | GRIA1CACNG8ALPLKMO | |
| SCHEMBL70682 | 0.72 | — | — | |
| SCHEMBL23239915 | 0.72 | PGK1 (0.41) | GRIA1CACNG8PGK1SLC1A5NOTUM | |
| SCHEMBL10892087 | 0.72 | PGK1 (0.37) | GRIA1CACNG8PGK1SLC1A5NOTUM | |
| SCHEMBL20118715 | 0.72 | EPAS1 (0.44) | GRIA1CACNG8SLC1A5HSD11B1 | |
| SCHEMBL29795913 | 0.69 | CYP3A4 (0.37) | GRIA1CACNG8PGK1SLC1A5NOTUM | |
| SCHEMBL23213536 | 0.69 | CYP3A4 (0.37) | GRIA1CACNG8PGK1SLC1A5NOTUM | |
| SCHEMBL13073831 | 0.69 | PGK1 (0.42) | GRIA1CACNG8PGK1SLC1A5NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604484-B2 | Indolone compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-31 | — | — | US | disclosed |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604484-B2 | Indolone compounds and their use as AMPA receptor modulators | GRIN3A, GRIN1, GRIN2B | GRIA1 23/4885CACNG8 317/4885PGK1 1722/4885 |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN3A, GRIN1, GRIN2B | GRIA1 23/4885CACNG8 317/4885PGK1 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.